The Latest
-
Will Walgreens’ store closures derail its clinical trial aims?
Despite a plan to shutter 1,200 stores, the company’s chief clinical trials officer said the pharmacy juggernaut remains committed to drug research.
-
Keytruda represents almost half of Merck’s sales, and a new formulation could fend off rivals
A subcutaneous version of Merck’s Keytruda was as effective as the infused version in a late-stage study, but the company won’t be the first to market.
-
Pfizer, under pressure to change, names oncology head as new R&D chief
Chris Boshoff will replace Mikael Dolsten, who’s stepping down after 15 years leading research at the drugmaker.
-
What might a Trump administration mean for the Biosecure Act?
It’s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners — it’s just a matter of when.
-
What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
AbbVie’s head of R&D cures has lofty ambitions to end diseases like HIV through a community of researchers that work as one.
-
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
-
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.
-
The first MASH drug could open the door for others — including GLP-1s
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
-
Where are they now? 4 biotechs that soared then crashed during the pandemic
How Novavax and others have restructured and trudged forward after their COVID-era high.
-
Trump names RFK Jr. as his pick to lead HHS
If confirmed to the role, Robert F. Kennedy Jr. would oversee the country's top health agencies, including the Food and Drug Administration and the Centers for Disease Control and Prevention.
Updated Nov. 14, 2024 -
Profile
Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past
While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.
-
From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies
As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.
-
Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’
As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.
-
Pharma’s grip on cancer R&D is having unintended consequences
A pair of studies paint a complicated picture of funding and missed research opportunities.
-
What RFK Jr.’s influence could mean for pharma
Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare.
-
Spravato is just the beginning in a new wave of depression meds
Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.
-
With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC
Speculation around pharma dealmaking and the next FDA commissioner has begun.
-
Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in
Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.
-
An RNAi renaissance is creating a new generation of startups
Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.
-
A diabetes drug, twice rejected, stumbles again — but its developer persists
After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.
-
Profile
CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure
Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.
-
Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.
-
Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s
Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.
-
Pharma takes aim at a wily foe — the Epstein-Barr virus
The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.
-
A sickle cell cure exists. But patients need more than just gene therapy.
Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.